
NavDx® is the only Medicare-covered MRD test for HPV-positive Head &amp; Neck and Anal Cancers


Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell

<p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">NavDx<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> is the only Medicare-covered MRD test for HPV-positive Head &amp; Neck and Anal Cancers</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CDNA">CDNA</a>), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml" id="news-body-cta">This press release features multimedia. View the full release here: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260701539330/en/" rel="nofollow">https://www.businesswire.com/news/home/20260701539330/en/</a></p><div xmlns="http://www.w3.org/1999/xhtml" id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img xmlns="http://www.w3.org/1999/xhtml" src="https://mms.businesswire.com/media/20260701539330/en/2843699/4/CareDx_Completes_Acquisition_of_Naveris_Extending_Leadership_into_High-Growth_Specialty_Oncology.jpg" alt=""></img></div><p xmlns="http://www.w3.org/1999/xhtml">
Naveris’s lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — including human papillomavirus (HPV)-associated head and neck and anal cancers — from diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Over 130,000 NavDx tests have been commercially reported to date. The test first obtained Medicare coverage in 2023 and has an ADLT Medicare reimbursement rate of $1,800. In 2025, Naveris generated approximately $35 million in revenue, more than doubling year-over-year. CareDx now offers a portfolio of precision diagnostic testing services across solid organ transplant, cell therapy-based hematologic malignancies, and viral-mediated cancers, addressing a U.S. market that is now estimated to exceed $12 billion.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;CareDx wins by commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease — that&#39;s our growth model,&#34; said John Hanna, President and Chief Executive Officer of CareDx. &#34;NavDx fits that model precisely. We believe we have the platform and the focus to scale it, and we expect it to be a meaningful contributor to CareDx’s growth from day one.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
Beginning in the third quarter of 2026, Naveris will be included in CareDx’s consolidated financial results.

</p><p xmlns="http://www.w3.org/1999/xhtml">
About CareDx
<br xmlns="http://www.w3.org/1999/xhtml"></br>CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.caredx.com&amp;esheet=54563494&amp;newsitemid=20260701539330&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=1&amp;md5=a9c845fb2560ddbc6549dbae90f3ff5f" shape="rect">www.caredx.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Forward Looking Statements
<br xmlns="http://www.w3.org/1999/xhtml"></br>This press release includes forward-looking statements related to CareDx including statements regarding the expected completion and timing of the acquisition, the anticipated impact of the transaction on CareDx’s business, financial profile, and operating results, the benefits of the Naveris product, reimbursement coverage for the Naveris product, the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2026, the ability of CareDx to advance Naveris’ platform technologies on a timely basis, if at all, the ability to satisfy all closing conditions and complete the transaction, difficulties or unanticipated expenses in connection with integrating the companies, and other statements that are not historical facts. These forward-looking statements are based on information currently available to CareDx and its current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the failure to obtain required regulatory approvals or satisfy closing conditions, delays in completing the transaction, general economic and market factors, and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these risks may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260701539330r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260701539330/en/" rel="nofollow">https://www.businesswire.com/news/home/20260701539330/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx, Inc.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Media
<br xmlns="http://www.w3.org/1999/xhtml"></br>Natasha Moshirian Wagner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:nwagner@CareDx.com" shape="rect">nwagner@CareDx.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Investor Relations
<br xmlns="http://www.w3.org/1999/xhtml"></br>Caroline Corner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@CareDx.com" shape="rect">investor@CareDx.com</a>

</p>

CDNA

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

CareDx Completes Naveris Acquisition, Expanding NavDx MRD Market to $12B+

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NavDx® is the only Medicare-covered MRD test for HPV-positive Head &amp;amp; Neck and Anal Cancers


Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>CareDx has completed its acquisition of Naveris, integrating NavDx into its diagnostics platform and expanding its reach in viral-mediated cancers. NavDx is Medicare-covered and targets HPV-related head and neck and anal cancers, with over 130,000 tests and a Medicare reimbursement of $1,800 per ADLT. The deal lifts CareDx&#039;s addressable market to exceed $12 billion and will be reflected in consolidated results starting in Q3 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CareDx completes Naveris acquisition; closing conditions met.</li><li>NavDx remains Medicare-covered; first and only MRD test for HPV-driven cancers.</li><li>Acquisition expands CareDx’s addressable market to over $12 billion.</li><li>2025 NavDx revenue about $35 million; tests exceed 130,000 to date.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>CareDx, Inc. (CDNA)</strong>: Acquisition completed; NavDx integration expected to accelerate growth and expand platform across transplant and oncology diagnostics.</li><li><strong>Naveris, Inc. (Private)</strong>: Acquired; NavDx platform to be integrated into CareDx; potential revenue uplift depends on integration execution and reimbursement dynamics.</li></ul>
  </section>

  <section data-block="category">
    <h3>M&amp;A</h3>
    <p>M&amp;A driven corporate development that expands product portfolio and total addressable market, enhancing growth trajectory.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>NavDx Medicare coverage supports near-term profitability.</li><li>Consolidation becomes effective in Q3 2026, boosting revenue visibility.</li><li>TAM expansion to over $12B broadens growth runway.</li><li>Deal-driven sentiment could lift CDNA shares in weeks ahead.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>NavDx is Medicare-covered MRD test for HPV-positive head/neck and anal cancers.</li><li>Over 130,000 NavDx tests have been commercially reported to date.</li><li>Medicare ADLT reimbursement rate for NavDx: $1,800.</li><li>CareDx 2025 NavDx revenue: approximately $35 million, more than doubling YoY.</li><li>Total addressable US market now estimated at &gt;$12 billion.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Long CDNA on NavDx expansion; material revenue contribution expected from 2026 onward.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">NavDx<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> is the only Medicare-covered MRD test for HPV-positive Head &amp; Neck and Anal Cancers</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CDNA">CDNA</a>), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml" id="news-body-cta">This press release features multimedia. View the full release here: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260701539330/en/" rel="nofollow">https://www.businesswire.com/news/home/20260701539330/en/</a></p><div xmlns="http://www.w3.org/1999/xhtml" id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img xmlns="http://www.w3.org/1999/xhtml" src="https://mms.businesswire.com/media/20260701539330/en/2843699/4/CareDx_Completes_Acquisition_of_Naveris_Extending_Leadership_into_High-Growth_Specialty_Oncology.jpg" alt=""></img></div><p xmlns="http://www.w3.org/1999/xhtml">
Naveris’s lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — including human papillomavirus (HPV)-associated head and neck and anal cancers — from diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Over 130,000 NavDx tests have been commercially reported to date. The test first obtained Medicare coverage in 2023 and has an ADLT Medicare reimbursement rate of $1,800. In 2025, Naveris generated approximately $35 million in revenue, more than doubling year-over-year. CareDx now offers a portfolio of precision diagnostic testing services across solid organ transplant, cell therapy-based hematologic malignancies, and viral-mediated cancers, addressing a U.S. market that is now estimated to exceed $12 billion.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;CareDx wins by commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease — that&#39;s our growth model,&#34; said John Hanna, President and Chief Executive Officer of CareDx. &#34;NavDx fits that model precisely. We believe we have the platform and the focus to scale it, and we expect it to be a meaningful contributor to CareDx’s growth from day one.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
Beginning in the third quarter of 2026, Naveris will be included in CareDx’s consolidated financial results.

</p><p xmlns="http://www.w3.org/1999/xhtml">
About CareDx
<br xmlns="http://www.w3.org/1999/xhtml"></br>CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.caredx.com&amp;esheet=54563494&amp;newsitemid=20260701539330&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=1&amp;md5=a9c845fb2560ddbc6549dbae90f3ff5f" shape="rect">www.caredx.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Forward Looking Statements
<br xmlns="http://www.w3.org/1999/xhtml"></br>This press release includes forward-looking statements related to CareDx including statements regarding the expected completion and timing of the acquisition, the anticipated impact of the transaction on CareDx’s business, financial profile, and operating results, the benefits of the Naveris product, reimbursement coverage for the Naveris product, the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2026, the ability of CareDx to advance Naveris’ platform technologies on a timely basis, if at all, the ability to satisfy all closing conditions and complete the transaction, difficulties or unanticipated expenses in connection with integrating the companies, and other statements that are not historical facts. These forward-looking statements are based on information currently available to CareDx and its current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the failure to obtain required regulatory approvals or satisfy closing conditions, delays in completing the transaction, general economic and market factors, and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these risks may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260701539330r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260701539330/en/" rel="nofollow">https://www.businesswire.com/news/home/20260701539330/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx, Inc.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Media
<br xmlns="http://www.w3.org/1999/xhtml"></br>Natasha Moshirian Wagner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:nwagner@CareDx.com" shape="rect">nwagner@CareDx.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Investor Relations
<br xmlns="http://www.w3.org/1999/xhtml"></br>Caroline Corner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@CareDx.com" shape="rect">investor@CareDx.com</a>

</p>

CareDx has completed its acquisition of Naveris, integrating NavDx into its diagnostics platform and expanding its reach in viral-mediated cancers. NavDx is Medicare-covered and targets HPV-related head and neck and anal cancers, with over 130,000 tests and a Medicare reimbursement of $1,800 per ADLT. The deal lifts CareDx's addressable market to exceed $12 billion and will be reflected in consolidated results starting in Q3 2026.

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

M&A

Related News